Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer

Jocelyn Aspa 3 hours ago

BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study

GlobeNewswire 8 hours ago

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

GlobeNewswire 13 days ago

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 - 13

GlobeNewswire November 4, 2024

BriaCell reports survival data from Phase 2 study

Jocelyn Aspa October 22, 2024

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

GlobeNewswire October 22, 2024

BriaCell Therapeutics advances Phase 3 MBC clinical study

Jocelyn Aspa October 15, 2024

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

GlobeNewswire October 15, 2024

BriaCell Therapeutics Announces Closing of $5 Million Offering

GlobeNewswire October 2, 2024

BriaCell Therapeutics Announces $5 Million Offering

GlobeNewswire October 1, 2024

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor

GlobeNewswire October 1, 2024

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

GlobeNewswire September 18, 2024

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

GlobeNewswire September 12, 2024

BriaCell Therapeutics Announces $8.5 Million Offering

GlobeNewswire September 11, 2024

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

GlobeNewswire September 11, 2024

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+(TM) for Prostate Cancer

GlobeNewswire September 10, 2024

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire September 9, 2024

BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer

GlobeNewswire July 18, 2024

BriaCell Presents Clinical Efficacy Data at ASCO 2024

GlobeNewswire June 3, 2024

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS(TM) in Advanced Metastatic Breast Cancer

GlobeNewswire May 30, 2024